[
    [
        {
            "time": "",
            "original_text": "306家药企晒2020成绩单！超40家亏损，77家翻倍，云南白药、复星……狂赚超30亿 亏损",
            "features": {
                "keywords": [
                    "药企",
                    "2020成绩单",
                    "亏损",
                    "翻倍",
                    "云南白药",
                    "复星"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "306家药企晒2020成绩单！超40家亏损，77家翻倍，云南白药、复星……狂赚超30亿 亏损",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "麦格理：升上海医药(2607.HK)目标价至21.75港元评级“跑赢大市”",
            "features": {
                "keywords": [
                    "麦格理",
                    "上海医药",
                    "目标价",
                    "21.75港元",
                    "跑赢大市"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "麦格理：升上海医药(2607.HK)目标价至21.75港元评级“跑赢大市”",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]